{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:37:19Z","timestamp":1782286639706,"version":"3.54.5"},"reference-count":58,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["KQTD20190929174023858"],"award-info":[{"award-number":["KQTD20190929174023858"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20535"],"award-info":[{"award-number":["U23A20535"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304603"],"award-info":[{"award-number":["82304603"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273429"],"award-info":[{"award-number":["82273429"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102879"],"award-info":[{"award-number":["82102879"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404752"],"award-info":[{"award-number":["82404752"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515012667"],"award-info":[{"award-number":["2023A1515012667"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.dmd.2025.100192","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:05:40Z","timestamp":1761782740000},"page":"100192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Metabolomics and lipidomics predictor of survival in hepatocellular carcinoma patients receiving tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy"],"prefix":"10.1016","volume":"53","author":[{"given":"Shaoxing","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosheng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruitong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumyuet","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7094-2296","authenticated-orcid":false,"given":"Huichang","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.dmd.2025.100192_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"10.1016\/j.dmd.2025.100192_bib2","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.dmd.2025.100192_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase iii, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.dmd.2025.100192_bib4","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.dmd.2025.100192_bib5","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dmd.2025.100192_bib6","article-title":"Lenvatinib plus camrelizumab vs. lenvatinib monotherapy as first-line treatment for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100192_bib7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.dmd.2025.100192_bib8","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1111\/cas.13806","article-title":"Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model","volume":"109","author":"Kimura","year":"2018","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.dmd.2025.100192_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway","volume":"14","author":"Kato","year":"2019","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.dmd.2025.100192_bib10","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.dmd.2025.100192_bib11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41580-019-0108-4","article-title":"Identification of bioactive metabolites using activity metabolomics","volume":"20","author":"Rinschen","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100192_bib12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/mas.21548","article-title":"Metabolomics toward personalized medicine","volume":"38","author":"Jacob","year":"2019","journal-title":"Mass Spectrom Rev"},{"issue":"8","key":"10.1016\/j.dmd.2025.100192_bib13","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1016\/j.apsb.2023.05.021","article-title":"Metabolomics in drug research and development: the recent advances in technologies and applications","volume":"13","author":"Pang","year":"2023","journal-title":"Acta Pharm Sin B"},{"issue":"7","key":"10.1016\/j.dmd.2025.100192_bib14","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1016\/j.apsb.2025.05.009","article-title":"Artificial intelligence and anti-cancer drugs\u2019 response","volume":"15","author":"Long","year":"2025","journal-title":"Acta Pharm Sin B"},{"issue":"12","key":"10.1016\/j.dmd.2025.100192_bib15","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41575-021-00502-9","article-title":"Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests","volume":"18","author":"Masoodi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.dmd.2025.100192_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009399","article-title":"Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1\/PD-L1 inhibitors","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.dmd.2025.100192_bib17","article-title":"Predicting effect of anti-PD-1\/PD-L1 inhibitors therapy for hepatocellular carcinoma by detecting plasma metabolite based on UHPLC-MS","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100192_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113877","article-title":"Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy","volume":"43","author":"Li","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.dmd.2025.100192_bib19","article-title":"Plasma lipidomic profiling of thiopurine-induced leukopenia after NUDT15 genotype-guided dosing in Chinese IBD patients","volume":"10","author":"Li","year":"2023","journal-title":"Front Nutr"},{"issue":"4","key":"10.1016\/j.dmd.2025.100192_bib20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41587-023-01690-2","article-title":"Integrative analysis of multimodal mass spectrometry data in MZmine 3","volume":"41","author":"Schmid","year":"2023","journal-title":"Nat Biotechnol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100192_bib21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nmeth.3393","article-title":"MS-DIAL: data-independent MS\/MS deconvolution for comprehensive metabolome analysis","volume":"12","author":"Tsugawa","year":"2015","journal-title":"Nat Methods"},{"issue":"22","key":"10.1016\/j.dmd.2025.100192_bib22","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1007\/s00216-017-0483-7","article-title":"Optimization of lipid extraction and analytical protocols for UHPLC-ESI-HRMS-based lipidomic analysis of adherent mammalian cancer cells","volume":"409","author":"Zhang","year":"2017","journal-title":"Anal Bioanal Chem"},{"issue":"5","key":"10.1016\/j.dmd.2025.100192_bib23","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1021\/acs.analchem.8b05592","article-title":"Systematic error removal using random forest for normalizing large-scale untargeted lipidomics data","volume":"91","author":"Fan","year":"2019","journal-title":"Anal Chem"},{"issue":"17","key":"10.1016\/j.dmd.2025.100192_bib24","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1158\/1078-0432.CCR-22-0791","article-title":"FOXM1 Variant contributes to gefitinib resistance via activating Wnt\/\u03b2-catenin signal pathway in patients with non-small cell lung cancer","volume":"28","author":"Guan","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.dmd.2025.100192_bib25","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/1078-0432.CCR-23-2357","article-title":"Germline USP36 mutation confers resistance to EGFR-TKIs by upregulating MLLT3 expression in patients with non-small cell lung cancer","volume":"30","author":"Guan","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.dmd.2025.100192_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13148-019-0730-1","article-title":"Statistical predictions with glmnet","volume":"11","author":"Engebretsen","year":"2019","journal-title":"Clin Epigenet"},{"issue":"W1","key":"10.1016\/j.dmd.2025.100192_bib27","doi-asserted-by":"crossref","first-page":"W398","DOI":"10.1093\/nar\/gkae253","article-title":"MetaboAnalyst 6.0: towards a unified platform for metabolomics data processing, analysis and interpretation","volume":"52","author":"Pang","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.dmd.2025.100192_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12931-024-02885-0","article-title":"Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a potential biomarker for atezolizumab-treated patients with extensive stage small cell lung cancer","volume":"25","author":"Zhang","year":"2024","journal-title":"Respir Res"},{"issue":"22","key":"10.1016\/j.dmd.2025.100192_bib29","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1002\/cam4.6645","article-title":"Real-world outcomes of 18,186 metastatic solid tumor outpatients: baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy","volume":"12","author":"Goldschmidt","year":"2023","journal-title":"Cancer Med"},{"issue":"33","key":"10.1016\/j.dmd.2025.100192_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau6085","article-title":"Structure and function of the immune system in the spleen","volume":"4","author":"Lewis","year":"2019","journal-title":"Sci Immunol"},{"issue":"10","key":"10.1016\/j.dmd.2025.100192_bib31","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1515\/hsz-2018-0181","article-title":"Sphingolipids in early viral replication and innate immune activation","volume":"399","author":"Bezgovsek","year":"2018","journal-title":"Biol Chem"},{"issue":"6","key":"10.1016\/j.dmd.2025.100192_bib32","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/s12276-023-01018-9","article-title":"Functional roles of sphingolipids in immunity and their implication in disease","volume":"55","author":"Lee","year":"2023","journal-title":"Exp Mol Med"},{"issue":"7503","key":"10.1016\/j.dmd.2025.100192_bib33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nature13475","article-title":"Sphingolipid metabolites in inflammatory disease","volume":"510","author":"Maceyka","year":"2014","journal-title":"Nature"},{"issue":"7_Supplement","key":"10.1016\/j.dmd.2025.100192_bib34","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-2968","article-title":"Development of anti-APP antibody targeting APP\/CNTN4 axis as a novel cancer immunotherapy","volume":"83","author":"Cha","year":"2023","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.dmd.2025.100192_bib35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1161\/ATVBAHA.108.179283","article-title":"Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses","volume":"30","author":"Yvan-Charvet","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.dmd.2025.100192_bib36","article-title":"Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100192_bib37","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1002\/hep.26130","article-title":"Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma","volume":"57","author":"Wang","year":"2013","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.dmd.2025.100192_bib38","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.3390\/cancers13112787","article-title":"NMR-based lipid metabolite profiles to predict outcomes in patients undergoing interventional therapy for a hepatocellular carcinoma (HCC): a substudy of the SORAMIC Trial","volume":"13","author":"Geyer","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.dmd.2025.100192_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102973","article-title":"Plasma metabolomic profiles in liver cancer patients following stereotactic body radiotherapy","volume":"59","author":"Ng","year":"2020","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.dmd.2025.100192_bib40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/HEP.0000000000000553","article-title":"Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma","volume":"79","author":"Li","year":"2024","journal-title":"Hepatology"},{"issue":"7596","key":"10.1016\/j.dmd.2025.100192_bib41","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nature17412","article-title":"Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism","volume":"531","author":"Yang","year":"2016","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.dmd.2025.100192_bib42","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.ccell.2023.04.016","article-title":"Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity","volume":"41","author":"Yan","year":"2023","journal-title":"Cancer Cell"},{"issue":"107","key":"10.1016\/j.dmd.2025.100192_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adr4795","article-title":"Uptake of lipids from ascites drives NK cell metabolic dysfunction in ovarian cancer","volume":"10","author":"Slattery","year":"2025","journal-title":"Sci Immunol"},{"key":"10.1016\/j.dmd.2025.100192_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.semcancer.2023.02.010","article-title":"Obesity and immune-checkpoint inhibitors in advanced melanoma: a meta-analysis of survival outcomes from clinical studies","volume":"91","author":"Roccuzzo","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.dmd.2025.100192_bib45","article-title":"Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.dmd.2025.100192_bib46","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.3390\/molecules25102436","article-title":"Sphingosine 1-phosphate signaling and metabolism in chemoprevention and chemoresistance in colon cancer","volume":"25","author":"Grb\u010di\u0107","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.dmd.2025.100192_bib47","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1038\/ncomms7956","article-title":"Enterobacteria-secreted particles induce production of exosome-like S1P-containing particles by intestinal epithelium to drive Th17-mediated tumorigenesis","volume":"6","author":"Deng","year":"2015","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.dmd.2025.100192_bib48","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.1038\/s41467-024-51495-3","article-title":"Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial","volume":"15","author":"Dong","year":"2024","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.dmd.2025.100192_bib49","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/17425255.2013.748749","article-title":"The role of sphingolipids in drug metabolism and transport","volume":"9","author":"Kim","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"9","key":"10.1016\/j.dmd.2025.100192_bib50","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20241799","article-title":"S1PR1 regulates lymphatic valve development and tertiary lymphoid organ formation in the ileum","volume":"222","author":"Geng","year":"2025","journal-title":"J Exp Med"},{"issue":"9","key":"10.1016\/j.dmd.2025.100192_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107693","article-title":"Identification of S1PR4 as an immune modulator for favorable prognosis in HNSCC through machine learning","volume":"26","author":"Huang","year":"2023","journal-title":"iScience"},{"issue":"4","key":"10.1016\/j.dmd.2025.100192_bib52","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/14656566.2023.2178898","article-title":"An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis","volume":"24","author":"Dumitrescu","year":"2023","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"10.1016\/j.dmd.2025.100192_bib53","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1172\/JCI136068","article-title":"FTY720 reactivates cryptococcal granulomas in mice through S1P receptor 3 on macrophages","volume":"130","author":"Bryan","year":"2020","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.dmd.2025.100192_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006343","article-title":"Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor","volume":"11","author":"Gao","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.dmd.2025.100192_bib55","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1038\/s41467-023-37875-1","article-title":"Metabolomic differentiation of benign vs malignant pulmonary nodules with high specificity via high-resolution mass spectrometry analysis of patient sera","volume":"14","author":"Yao","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.dmd.2025.100192_bib56","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41422-022-00614-0","article-title":"Comprehensive metabolomics expands precision medicine for triple-negative breast cancer","volume":"32","author":"Xiao","year":"2022","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.dmd.2025.100192_bib57","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41467-024-46043-y","article-title":"Metabolomic machine learning predictor for diagnosis and prognosis of gastric cancer","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.dmd.2025.100192_bib58","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1136\/gutjnl-2022-328708","article-title":"Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)","volume":"72","author":"Weiss","year":"2023","journal-title":"Gut"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625095017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625095017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:14:29Z","timestamp":1773879269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625095017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0090955625095017"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100192","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolomics and lipidomics predictor of survival in hepatocellular carcinoma patients receiving tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100192","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100192"}}